Johnson & Johnson delivered higher than expected adjusted earnings and raised its 2011 guidance, driven by strong pharmaceutical performance and strategic partnerships. While there are challenges in the Consumer segment and increased remediation costs, the positive outlook and robust pipeline support investor confidence in the short term.

[1]